Wound Healing Protocol

Overview

Wound healing is a complex, multi-phase biological process involving hemostasis, inflammation, proliferation, and remodeling. Each phase involves distinct cellular and molecular events, and disruption at any stage can lead to delayed healing or chronic wounds. Peptide-based approaches to wound healing aim to support and accelerate these natural processes through targeted signaling.

This protocol combines systemic peptide administration with local topical application, addressing both the deep tissue repair cascade and the surface-level wound environment. The three primary compounds — BPC-157, TB-500, and GHK-Cu — each contribute through distinct mechanisms, making them complementary rather than redundant.

BPC-157 has been studied extensively in preclinical wound models for its ability to accelerate angiogenesis and modulate nitric oxide pathways at the wound site. TB-500 (Thymosin Beta-4) supports cellular migration and reduces inflammatory signaling through actin regulation. GHK-Cu, a naturally occurring copper peptide, has demonstrated the ability to stimulate collagen synthesis, attract immune cells to wound sites, and promote the formation of new blood vessels in skin tissue.

Compounds Involved

Protocol Structure

This protocol uses a dual-pathway approach: systemic injectable peptides to support the internal healing cascade, and topical GHK-Cu to directly support the wound surface and surrounding tissue.

Systemic Component (Weeks 1–8)

Phase 1: Acute Support (Weeks 1–4)

BPC-157:

• Dose: 250–500 mcg per day
• Frequency: Twice daily (split dosing recommended — e.g., 250 mcg morning, 250 mcg evening)
• Injection site: Subcutaneous, as close to the wound area as practical without injecting into the wound itself. For internal or inaccessible wounds, standard abdominal SubQ injection is used
• Rationale: Higher frequency during the acute phase supports the initial inflammatory-to-proliferative transition

TB-500:

• Dose: 2.5–5 mg per injection
• Frequency: Twice per week (e.g., Monday and Thursday)
• Injection site: Subcutaneous, abdomen or proximal to the wound area
• Rationale: TB-500's role in cell migration is most critical during the early proliferative phase when fibroblasts and endothelial cells are moving into the wound bed

Phase 2: Remodeling Support (Weeks 5–8)

BPC-157:

• Dose: 200–250 mcg per day
• Frequency: Once daily
• Continue for: 4 additional weeks, or longer for chronic or slow-healing wounds

TB-500:

• Dose: 2 mg per injection
• Frequency: Once per week
• Continue for: 4 additional weeks

Topical Component (Weeks 1–12)

GHK-Cu:

• Form: 1–2% GHK-Cu cream or serum
• Application: Apply a thin layer to the wound margins and surrounding skin twice daily (morning and evening)
• Duration: Continue throughout the systemic protocol and for 2–4 weeks beyond, as the remodeling phase of wound healing can extend for months
• Important: Apply to clean, dry skin around the wound — not directly into open wound cavities. Once the wound has closed, application over the healed area supports collagen remodeling and scar maturation

Phase Summary Table

Wound Type Considerations

Different wound types may benefit from adjusted approaches within this framework:

• Surgical incisions: The standard protocol applies well. Topical GHK-Cu can begin once sutures are removed and the wound surface is closed
• Lacerations and abrasions: Topical application can begin early on the wound margins. Systemic peptides support deeper tissue repair
• Chronic wounds (ulcers, non-healing wounds): May require extended protocols beyond 8 weeks. The loading phase doses may be maintained longer before transitioning to maintenance
• Burn wounds: GHK-Cu has been studied specifically in burn models. Topical application to healed burn margins may support collagen remodeling and reduce hypertrophic scarring
• Post-surgical recovery: Timing peptide administration to begin shortly after surgery may optimize the healing timeline. Consult the Recovery Protocol for additional post-surgical strategies

Important Considerations

• Infection takes priority: No peptide protocol replaces proper wound care, debridement, or antibiotic therapy when infection is present. Wounds must be clean and free of active infection before topical peptide application.
• Do not inject into open wounds: Subcutaneous injections should be placed near, not in, the wound area. Injecting into compromised tissue risks introducing bacteria and disrupting the wound bed.
• Collagen remodeling is slow: The remodeling phase of wound healing can last 6–24 months. GHK-Cu topical application during this period supports ongoing collagen cross-linking and organization.
• Nutrition matters: Wound healing demands increased protein, vitamin C, zinc, and caloric intake. Peptides cannot compensate for nutritional deficiencies.
• Monitor for adverse reactions: Any signs of worsening redness, warmth, swelling, or discharge at the wound site should prompt medical evaluation regardless of peptide use.
• Storage and reconstitution: See Reconstitution for preparation of injectable peptides. GHK-Cu topical products should be stored according to manufacturer specifications, typically at room temperature away from direct sunlight.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.